Vaccines for Streptococcus agalactiae : current status and future perspectives.
| Autor: | Pena JMS; Laboratory of Molecular Biology and Physiology of Streptococci, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University - UERJ, Rio de Janeiro, Brazil., Lannes-Costa PS; Laboratory of Molecular Biology and Physiology of Streptococci, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University - UERJ, Rio de Janeiro, Brazil., Nagao PE; Laboratory of Molecular Biology and Physiology of Streptococci, Institute of Biology Roberto Alcantara Gomes, Rio de Janeiro State University - UERJ, Rio de Janeiro, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Frontiers in immunology [Front Immunol] 2024 Jun 14; Vol. 15, pp. 1430901. Date of Electronic Publication: 2024 Jun 14 (Print Publication: 2024). |
| DOI: | 10.3389/fimmu.2024.1430901 |
| Abstrakt: | A maternal vaccine to protect newborns against invasive Streptococcus agalactiae infection is a developing medical need. The vaccine should be offered during the third trimester of pregnancy and induce strong immune responses and placental transfer of protective antibodies. Polysaccharide vaccines against S. agalactiae conjugated to protein carriers are in advanced stages of development. Additionally, protein-based vaccines are also in development, showing great promise as they can provide protection regardless of serotype. Furthermore, safety concerns regarding a new vaccine are the main barriers identified. Here, we present vaccines in development and identified safety, cost, and efficacy concerns, especially in high-need, low-income countries. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Pena, Lannes-Costa and Nagao.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|